Abnormal Regulation of Pancreatic Glucagon Secretion in Obese Fa/fa Rats

Overview

Journal Diabetologia

Specialty Endocrinology

Date 1988 Apr 1

PMID 3384221

Authors

F Rohner-Jeanrenaud

B Jeanrenaud

Affiliations

Soon will be listed here.

Abstract

The results reported in the literature regarding glucagonaemia in genetically obese fa/fa rats are conflicting: normal, increased or decreased plasma glucagon levels have been reported. Due to the existence of several molecules endowed with glucagon-like immunoreactivity, it was thought that the conflicting data could be related to the degree of specificity of the different glucagon antibodies. Three antibodies that all qualified as being specific for pancreatic glucagon were used. It was found that, depending on the antibody, absolute values of basal glucagonaemia or arginine-induced glucagon output varied quantitatively and qualitatively in both lean and obese rats. When non-extracted basal or stimulated plasma samples were passed on a G-50 Sephadex column, glucagon-like immunoreactivity was present over a wide range of molecular weights, indicating the presence of non-pancreatic glucagon molecules. When an ethanol extraction was used, the fractions eluting from the G-50 Sephadex column contained only pancreatic glucagon immunoreactivity. It is concluded that ethanol extraction is necessary for the measurement of the 3500 daltons glucagon. Using this methodology it was found that: (1) basal glucagonaemia was low but identical in the two groups of rats; (2) arginine-induced glucagon secretion was greater in obese than in lean animals; (3) glucagonaemia was decreased by glucose administration in lean but not in obese rats. It is concluded that there are, in obese animals, dysfunctions of glucagon output that may play a role in their abnormal glucose tolerance.

References

Hayek A, Woodside W . Correlation between morphology and function in isolated islets of the Zucker rat. Diabetes. 1979; 28(6):565-9. DOI: 10.2337/diab.28.6.565. View

Bryce G, Johnson P, Sullivan A, Stern J . Insulin and glucagon: plasma levels and pancreatic release in the genetically obese Zucker rat. Horm Metab Res. 1977; 9(5):366-70. DOI: 10.1055/s-0028-1093529. View

Jeanrenaud B . An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause. Diabetologia. 1985; 28(8):502-13. DOI: 10.1007/BF00281984. View

Jeanrenaud B, Halimi S, van de Werve G . Neuro-endocrine disorders seen as triggers of the triad: obesity--insulin resistance--abnormal glucose tolerance. Diabetes Metab Rev. 1985; 1(3):261-91. DOI: 10.1002/dmr.5610010303. View

Rosselin G, Assan R, Yalow R, Berson S . Separation of antibody-bound and unbound peptide hormones labelled with iodine-131 by talcum powder and precipitated silica. Nature. 1966; 212(5060):355-7. DOI: 10.1038/212355a0. View

ZUCKER L, Antoniades H . Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology. 1972; 90(5):1320-30. DOI: 10.1210/endo-90-5-1320. View

Rohner-Jeanrenaud F, Jeanrenaud B . Involvement of the cholinergic system in insulin and glucagon oversecretion of genetic preobesity. Endocrinology. 1985; 116(2):830-4. DOI: 10.1210/endo-116-2-830. View

Bobbioni E, Coscelli C . Portal levels of glucagon and insulin in VMH-lesioned rats. Horm Metab Res. 1980; 12(9):480-1. DOI: 10.1055/s-2007-999177. View

Goto Y, Carpenter R, Berelowitz M, Frohman L . Effect of ventromedial hypothalamic lesions on the secretion of somatostatin, insulin, and glucagon by the perfused rat pancreas. Metabolism. 1980; 29(10):986-90. DOI: 10.1016/0026-0495(80)90044-x. View

10.

Heding L, Rasmussen S . Determination of pancreatic and gut glucagon-like immunoreactivity (GLI) in normal and diabetic subjects. Diabetologia. 1972; 8(6):408-11. DOI: 10.1007/BF01212168. View

11.

EATON R, Oase R, Schade D . Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?. Metabolism. 1976; 25(3):245-9. DOI: 10.1016/0026-0495(76)90082-2. View

12.

von Schenck H, Nilsson O . Radioimmunoassay of extracted glucagon compared with three non-extraction assays. Clin Chim Acta. 1981; 109(2):183-91. DOI: 10.1016/0009-8981(81)90333-8. View

13.

Assan R, Attali J, Ballerio G, Boillot J, Girard J . Glucagon secretion induced by natural and artificial amino acids in the perfused rat pancreas. Diabetes. 1977; 26(4):300-7. DOI: 10.2337/diab.26.4.300. View

14.

Mayer J, ANDRUS S, SILIDES D . Effect of diethyldithiocarbamate and other agents on mice with the obese-hyperglycemic syndrome. Endocrinology. 1953; 53(5):572-81. DOI: 10.1210/endo-53-5-572. View

15.

Starke A, Erhardt G, Berger M, Zimmermann H . Elevated pancreatic glucagon in obesity. Diabetes. 1984; 33(3):277-80. DOI: 10.2337/diab.33.3.277. View

16.

Heding L . Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia. 1971; 7(1):10-9. DOI: 10.1007/BF02346248. View

17.

EATON R, Conway M, Schade D . Endogenous glucagon regulation in genetically hyperlipemic obese rats. Am J Physiol. 1976; 230(5):1336-41. DOI: 10.1152/ajplegacy.1976.230.5.1336. View

18.

Nishikawa K, Ikeda H, Matsuo T . Abnormal glucagon secretion in Zucker fatty rats. Horm Metab Res. 1981; 13(5):259-63. DOI: 10.1055/s-2007-1019239. View

19.

Alford F, Bloodm S, Nabarro J . Glucagon levels in normal and diabetic subjects: use of a specific immunoabsorbent for glucagon radioimmunoassay. Diabetologia. 1977; 13(1):1-6. DOI: 10.1007/BF00996319. View

20.

Ionescu E, Sauter J, Jeanrenaud B . Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol. 1985; 248(5 Pt 1):E500-6. DOI: 10.1152/ajpendo.1985.248.5.E500. View